Amplify Seymour Cannabis ETF

Curaleaf Holdings, Inc. released FY2025 Annual Earnings on February 27 After-Market (EST), Actual Revenue: USD 1.268 B (Forecast: USD 1.274 B), Actual EPS: USD -0.3587

Curaleaf Holdings, Inc. released FY2025 Q4 earnings on February 27 After-Market (EST), actual revenue USD 323.36 M (forecast USD 329.25 M), actual EPS USD -0.0904

Curaleaf Holdings, Inc. to Release FY2025 Q4 Earnings on February 26 After-Market EST, Forecast Revenue USD 328.27 M

Curaleaf Reports Strong Q4 Earnings and Plans to Exit Missouri Market

Curaleaf Holdings, Inc. released FY2025 9 Months Earnings on November 6 After-Market EST, with actual revenue of USD 944.77 M and EPS of USD -0.2695

Curaleaf Holdings, Inc. released FY2025 Q3 earnings on November 6 After-Market (EST), actual revenue USD 320.24 M (forecast USD 316.87 M), actual EPS USD -0.0838

Curaleaf Holdings, Inc. to Release FY2025 Q3 Earnings on November 5 After-Market EST, Forecast Revenue USD 317.11 M

Curaleaf Holdings, Inc. released FY2025 Semi-Annual earnings on August 6 After-Market EST, actual revenue USD 624.53M, actual EPS USD -0.1844

Curaleaf Holdings, Inc. released FY2025 Q2 earnings on August 6 After-Market EST, actual revenue USD 314.52 M (forecast USD 313.92 M), actual EPS USD -0.0839

Curaleaf Holdings, Inc. to Release FY2025 Q2 Earnings on August 6 After-Market EST, Forecast Revenue USD 314.71 M

Curaleaf Holdings, Inc. released FY2025 Q1 earnings on May 8 After-Market EST, actual revenue USD 310.01 M (forecast USD 311.26 M), actual EPS USD -0.0998

Curaleaf Holdings, Inc. to release FY2025 Q1 earnings on May 8 After-Market EST, forecast revenue USD 314.07 M

Curaleaf Holdings, Inc. released FY2024 earnings on March 4 After-Market EST, actual revenue USD 1.334 B (forecast USD 1.345 B), actual EPS USD -0.3214

Curaleaf Holdings, Inc. released FY2024 Q4 earnings on March 4 After-Market (EST), actual revenue $331.05M (forecast $332.23M), actual EPS -$0.1224

Curaleaf Holdings, Inc. to Release FY2024 Q4 Earnings on March 3, 2025, After-Market EST; Forecast Revenue 332.2 M USD

Curaleaf Holdings, Inc. released FY2024 Q3 earnings on November 7 After-Market (EST), actual revenue $330.53M (forecast $344.03M), actual EPS -0.0678

Curaleaf Holdings, Inc. released FY2024 9 Months Earnings on November 7 After-Market EST, with actual revenue of 1,011,748,000 USD and EPS of -0.1994

Curaleaf Holdings, Inc. to Release FY2024 Q3 Earnings on November 6 After-Market EST, Forecast Revenue 344.03 M USD

Curaleaf Holdings Inc. Launches New Jelly Series JAMS Remix

Boris Jordan, a cannabis tycoon, has been appointed as the CEO of Curaleaf Holdings

Actelis Networks

Acurx Pharmaceuticals

Golden Sun Tech

XCF Global

Tradr 2X Long NVTS Daily ETF

Commercial Vehicle

Beachbody

60 Degrees Pharmaceuticals

Sera Prognostics

Sagtec Global

TLRY

CURLF

CRON

CNBS

MSOS

The debate over Medicare's potential reimbursement for CBD products highlights the need for FDA oversight. Experts argue that without rigorous clinical trials and standardized manufacturing, the safety and efficacy of these products cannot be guaranteed. Variability in CBD formulations and labeling inaccuracies pose risks, especially for older adults. The discussion reflects a broader choice between treating cannabinoids as consumer products or as regulated medicines, with significant implications for patient care and industry standards.

Acceswire

Tilray Brands

Curaleaf Holdings, Inc.

Cronos

Green Thumb Industries Inc.

Canopy Growth

Trulieve Cannabis Corp.

Cresco Labs Inc.

Aurora Innovation - CW28

Aurora Cannabis

Clever Leaves

AdvisorShares Pure US Cannabis ETF

The $30 Billion CBD Question: Should Medicare Reimburse Cannabis Products Without FDA Approval?

Curaleaf Holdings, Inc. (OTCMKTS:CURLF) shares gapped down from $2.37 to $2.21 before trading at $2.25. Analysts have mixed ratings, with Zacks upgrading to 'hold' and ATB Cormark to 'outperform'. Curaleaf reported a quarterly EPS of ($0.05), exceeding estimates, with revenue of $333.07 million. The company has a market cap of $1.54 billion and a negative net margin of 18.08%. Despite a current 'Buy' consensus, some analysts suggest better investment opportunities exist.

Market Beat

Curaleaf (OTCMKTS:CURLF) Shares Gap Down   - What's Next?

TOKE

YOLO

The cannabis industry faces a reckoning as federal regulations tighten around hemp-derived THC products. Executives who rushed into the market may regret their decisions as the FDA prepares to enforce stricter rules, including cease-and-desist letters. While many companies focused on quick profits from intoxicating cannabinoid products, MMJ International Holdings took a different approach by developing FDA-compliant cannabinoid medicines. This divide could lead to a significant shift in the industry, favoring those who prioritize clinical validation over consumer brands.

Cambria Cannabis ETF

Amplify Alternative Harvest ETF

AdvisorShares Pure Cannabis ETF

From Billion-Dollar Hemp Drinks to FDA Cease-and-Desist Letters: The Cannabis Industry's Reckoning Is Coming

MSOX

A conflict has arisen between Housing Works, a nonprofit organization, and a cannabis dispensary owner, highlighting the challenges faced by businesses in this industry that lack access to conventional financial and other support. This incident underscores the difficulties faced by cannabis businesses, with an estimated total revenue of $17.5 billion in the United States in 2021, in navigating regulatory and operational hurdles without the usual resources available to other industries.

Unusual Whales

SNDL

AdvisorShares MSOS 2x Daily ETF

Village Farms

cbdMD

Innovative Industrial Properties

$2.5M dispute between Housing Works and cannabis dispensary owner highlights challenges for businesses in cannabis industry.

WEED

VICE

The Supreme Court is hearing arguments in United States v. Hemani, where the federal government equates regular marijuana users to "habitual drunkards" in terms of gun ownership rights. The case arises from a search of Ali Danial Hemani's home, where marijuana and a firearm were found. With 40 states allowing medical marijuana, the ruling could impact millions, including medical cannabis patients. The government cites historical laws against habitual drunkards to support its stance, while Hemani's lawyers argue that such comparisons are flawed, as early laws did not impose outright bans on gun possession for regular alcohol consumers.

ZeroHedge

Roundhill Cannabis ETF

AdvisorShares Vice - ETF

From Whiskey To Weed: A Second Amendment Fight

Curaleaf Holdings (OTC:CURLF) released its Q4 earnings report on February 26, 2026, beating estimated earnings by 37.5% with an EPS of $-0.05 compared to the estimate of $-0.08. Revenue increased by $2.01 million year-over-year. In the previous quarter, the company also exceeded EPS estimates, but the share price dropped by 14.74% the following day. For Q4 2024, the actual EPS was $-0.02, with revenue of $331.05 million. Investors can track all earnings releases on their earnings calendar.

benzinga_article

Curaleaf Holdings Q4 Earnings Report: What Investors Need to Know

Curaleaf Holdings, Inc. reported its fourth quarter and full year 2025 financial results, highlighting a net revenue of $333 million for Q4, with a 2% year-over-year increase. The company achieved a gross profit margin of 49% and an adjusted EBITDA of $69 million. For the full year, net revenue reached $1.27 billion, with an adjusted gross margin of 50%. Despite challenges, Curaleaf's international revenue grew significantly, and the company is transitioning to a growth strategy following a $500 million debt offering.

prnewswire

16:01 ETCuraleaf Reports Fourth Quarter and Full Year 2025 Results: Domestic and International Growth Accelerate with Gross Margin Expansion

Curaleaf Holdings (TSX:CURA) has gained investor attention following the opening of a new dispensary in Findlay, Ohio, increasing its total to five in the state and 162 nationwide. The company has seen a 7.89% share price return over 90 days and an 80.95% return over the past year. Analysts suggest Curaleaf is 30.1% undervalued with a fair value of CA$4.89, despite ongoing losses and market saturation. A DCF model estimates a future cash flow value of CA$15.73 per share, indicating potential growth opportunities amid regulatory challenges.

Simplywall

Curaleaf Holdings (TSX:CURA) Valuation Check After New Ohio Dispensary Expansion

The Trump administration signals that cannabis rescheduling is progressing, potentially boosting cannabis stocks. Rescheduling would move cannabis to Schedule III, allowing companies to deduct operating expenses. Recent positive signals include the White House's commitment to rescheduling despite criticism, FDA Commissioner affirming intent to promote medical research, and Trump's pardons of cannabis-related convictions. Investors remain optimistic about a significant market bounce upon rescheduling news.

CabotWealthNetwork

Cannabis Rescheduling Remains on Track

A new store opening has expanded Curaleaf Holdings, Inc.'s total retail locations in the United States to 162, with the addition of their fifth store in Ohio. The announcement was made on February 25, 2026, by the Connecticut-based company. Curaleaf is recognized as a prominent global supplier of cannabis products for consumers. The company's stock can be traded on the Toronto Stock Exchange under the symbol CURA and on the OTCQX under the symbol CURLF.

Curaleaf opens fifth Ohio dispensary, reaching 162 retail locations nationwide.

Curaleaf Holdings, Inc. has opened its fifth dispensary in Ohio, located in Findlay, increasing its national retail count to 162 locations. The new store aims to enhance access to high-quality cannabis for medical and adult-use customers in Northwest Ohio. Curaleaf's CEO, Boris Jordan, emphasized the company's commitment to quality and community engagement. The dispensary operates Monday to Saturday from 9 AM to 8 PM and Sunday from 9 AM to 7 PM. Curaleaf is a leading provider of cannabis products, listed on the TSX and OTCQX under CURA and CURLF, respectively.

StockTitan

Curaleaf Expands Retail Footprint with Dispensary Opening in Findlay, Ohio | CURLF Stock News

Curaleaf Holdings, Inc. (OTCMKTS:CURLF) shares rose 11.4% to $2.45 during mid-day trading, with 225,577 shares exchanged. Analysts have given the stock a "Buy" rating, with upgrades from Alliance Global Partners and ATB Cormark Capital Markets. Curaleaf has a market cap of $1.69 billion and operates in the cannabis sector, managing its supply chain from cultivation to retail. Despite the positive ratings, MarketBeat suggests there are better investment options than Curaleaf at this time.

Curaleaf (OTCMKTS:CURLF) Trading 11.4% Higher   - Time to Buy?

TD Securities has set a price target of C$0.10 for Decibel Cannabis (CVE:DB) and assigned a "hold" rating in a recent research report. On Tuesday, Decibel's shares remained flat at C$0.10, with a market capitalization of C$57.69 million. The company is involved in cannabis cultivation, processing, and retail operations in Canada. Despite the hold rating, analysts suggest there are better investment options available.

Decibel Cannabis (CVE:DB) Given a C$0.10 Price Target by TD Securities Analysts

MJUS

In Seattle on February 24th, 2026, Leading Retirement Solutions (LRS), a prominent cannabis 401(k) provider for over ten years, unveiled the pioneering Cannabis Industry Retirement Report. This release is significant for an industry that has traditionally experienced a lack of comprehensive data.

Amplify US Alternative Harvest ETF

Leading Retirement Solutions (LRS) releases first Cannabis Industry Retirement Report after a decade, marking a crucial milestone.

Curaleaf Holdings, Inc. has postponed its special shareholder meeting originally set for February 23, 2026, regarding its move from British Columbia to Delaware. The meeting will now be combined with the annual general meeting in Q2 2026 to enhance shareholder participation and reduce costs. A new date will be announced, and details will be provided in a management information circular. Analysts rate TSE:CURA stock as Hold with a C$3.50 price target, reflecting mixed financial challenges and technical strengths.

Tip Ranks

Curaleaf Delays Special Meeting, Plans Combined Vote on Move to Delaware

Amplify Seymour Cannabis ETF(CNBS.US)

The $30 Billion CBD Question: Should Medicare Reimburse Cannabis Products Without FDA Approval?

Curaleaf (OTCMKTS:CURLF) Shares Gap Down - What's Next?

From Billion-Dollar Hemp Drinks to FDA Cease-and-Desist Letters: The Cannabis Industry's Reckoning Is Coming

$2.5M dispute between Housing Works and cannabis dispensary owner highlights challenges for businesses in cannabis industry.

From Whiskey To Weed: A Second Amendment Fight